Claritin: Easing the Pain of Blockbuster Patent Expiry : Market Research Report

Claritin: Easing the Pain of Blockbuster Patent Expiry

Published by: Datamonitor

Published: Jan. 6, 2003 - 31 Pages

ABOUT DATAMONITOR HEALTHCARE

About the Immune Disorders and Inflammation pharmaceutical analysis team

EXECUTIVE SUMMARY

Introduction

Three key things you need to know about Claritin’s switch from Rx-to-OTC

CLARITIN’S STATUS BEFORE PATENT EXPIRY

Introduction

Drug overview

Patent expiry

Pressure from insurance companies

PATENT EXPIRY SURVIVAL STRATEGIES

Case Study: GlaxoSmithKline (formerly Glaxo Wellcome) - A patent expiry success

story

Schering-Plough’s strategies to recoup lost sales

Launch in Japan

Claritin/Singulair combination drug

Clarinex

EFFECTS OF OTC CLARITIN ON SCHERING-PLOUGH
REVENUES

sales

EFFECTS OF OTC CLARITIN ON OVERALL ALLERGIC RHINITIS
MARKET

Managed care

Generic competition

Effects on the market

Conclusion

APPENDIX

Disclaimer

DATASETS

Table 1: Global sales performance of Zantac, 1995-2001

Table 2: Global sales of the leading branded antihistamine drugs, 2000-2001

Table 3: Sales growth of leading antihistamines, 1997-2001

Table 4: Global sales of top allergic rhinitis drugs for the first three quarters of 2002

Table 5: Allergic rhinitis market forecast, 2002-09

Table 6: Major insurer’s non-sedating antihistamine policies post Claritin patent expiry

Table 7: Global sales forecasts for leading antihistamines, 2002-09

Table 8: Events affecting antihistamine brand forecasts

Figure 1: Global sales performance and growth of Zantac, 1995-2001

Figure 2: Analysis of Claritin survival strategies post patent expiry

Figure 3: Best case scenario of sales impact of switch to OTC Claritin

Figure 4: Proportion of the allergic rhinitis market held by the top three competitors, Q1-Q3 2002

Figure 5: Allergic rhinitis market sales forecast, 2002-09

Figure 6: Market share of the leading antihistamines in the allergic rhinitis market, 2002-09

Abstract

Introduction:
The December 2002 patent expiry of Claritin is severely impacting the antihistamine market. Schering-Plough is expected to lose nearly 70% of the profits generated by this drug that represented nearly 1/3 of the company’s 2001 revenue. Increased generic competition and decreased coverage by managed care will drive down profits of the remaining competitors, including Pfizer and Aventis. The market will decline at a CAGR of -3.9% between 2001 and 2009 due to this blockbuster patent expiry.

Scope:
* Detailed analysis of Claritin’s standing in the current antihistamine market and events leading up to its switch to OTC

* Case study of a past successful patent expiry

* Evaluation of Schering-Plough’s strategies to recoup sales lost as Claritin’s patent expires and the effects of these strategies on future revenues

* Examination of the effects of Claritin’s OTC availability on the overall allergic rhinitis market

* Market scenario forecast to 2009

Report Highlights:
Schering Plough’s strategies to limit the damage from blockbuster drug Claritin’s December 2002 patent expiry and switch to OTC status will be largely unsuccessful

Managed care organizations are taking full advantage of Claritin’s patent expiry and the entire antihistamine market will be severely impacted as a result. Co-pays are being raised for all non-sedating antihistamines and it is speculated that some insurance companies will remove them from formularies altogether.

The FDA approval of a number of generic formulations of Claritin in December 2002 and early 2003 will rub salt in Schering-Plough’s wounds. Generic versions of loratadine from J&J, Wyeth, Teva Pharmaceuticals and other manufacturers will be priced below OTC Claritin and further reduce the value of the antihistamine market.

Reasons to Purchase:
* Learn what Schering-Plough is doing to keep lost revenue to a minimum as Claritin's patent expires

* Quantify the impact of the availability of generic loratadine and decreased coverage by managed care on the allergic rhinitis market

* Discover where growth in the allergic rhinitis market will occur as this segment continues to mature

* Profit from Schering-Plough's losses as their biggest blockbuster loses control of the market

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Claritin: Easing the Pain of Blockbuster Patent Expiry

Table of Contents

Abstract